Thursday, 5 December 2024 | 13:30 - 13:50
ProTreg Trial – A phase I/IIa study to investigate the safety and tolerability of Tregs as an adjunctive therapy in CD kidney recipients following anti-thymocyte (ATG) induction therapy
Format:In-person
- In vivo engraftment (part 1)